Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Renalytix ( (GB:RENX) ) just unveiled an update.
Renalytix plc reported that interim Chief Financial Officer Joel Jung purchased an additional 500 American Depositary Shares at $2.85 per ADS, increasing his holding to 333,855 ordinary shares, or about 0.07% of the company’s issued share capital. The insider share purchase may be viewed by investors as a sign of confidence in the company’s prospects as it expands commercial deployment of its FDA-approved, Medicare-reimbursed kidneyintelX.dkd diagnostic across U.S. healthcare systems.
Renalytix continues to position kidneyintelX.dkd as a key tool in addressing unrecognized and uncontrolled diabetic kidney disease, which affects tens of millions of patients in the U.S. and U.K. With more than 15,000 patients already tested and strong real-world performance data, the company benefits from full Medicare reimbursement at $950 per reportable result and guideline recommendations, underscoring its growing role in the kidney disease diagnostics market.
The most recent analyst rating on (GB:RENX) stock is a Sell with a £5.50 price target. To see the full list of analyst forecasts on Renalytix stock, see the GB:RENX Stock Forecast page.
Spark’s Take on GB:RENX Stock
According to Spark, TipRanks’ AI Analyst, GB:RENX is a Neutral.
The score is held down primarily by weak financial performance (large losses, negative equity, and ongoing cash burn) and a bearish technical trend (price below key moving averages and negative MACD). Positive corporate updates and oversold signals provide some support, but they do not offset current financial and trend risk.
To see Spark’s full report on GB:RENX stock, click here.
More about Renalytix
Renalytix plc is an artificial intelligence-enabled in vitro diagnostics company focused on optimizing clinical management of kidney disease to improve patient outcomes. Its lead product, kidneyintelX.dkd, is the only FDA-approved and Medicare-reimbursed prognostic test for early-stage risk assessment in chronic diabetic kidney disease and is commercially offered in the U.S.
Average Trading Volume: 493,135
Technical Sentiment Signal: Sell
Current Market Cap: £24.47M
For a thorough assessment of RENX stock, go to TipRanks’ Stock Analysis page.